ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 35534238

Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.

Cabaud O and 16 others. Mol Cancer Ther, 2022. Cited by 63 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate. Papers, record 35534238. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35534238

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.
PubMed
Journal
Mol Cancer Ther
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
63
iCite
Relative citation ratio, by iCite
3.56
iCite
Revised in PubMed
2022-08-02
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cabaud OOlivierhttps://orcid.org/0000-0002-4704-5746
2Berger LLudovichttps://orcid.org/0000-0002-0482-1434
3Crompot EEmerencehttps://orcid.org/0000-0002-2761-6126
4Adélaide JJoséhttps://orcid.org/0000-0003-4364-9857
5Finetti PPascalhttps://orcid.org/0000-0002-2674-3123
6Garnier SSèverinehttps://orcid.org/0000-0002-7816-0667
7Guille AArnaudhttps://orcid.org/0000-0001-5747-562X
8Carbuccia NNadinehttps://orcid.org/0000-0002-3561-4315
9Farina AAnnehttps://orcid.org/0000-0002-6693-8590
10Agavnian EEmiliehttps://orcid.org/0000-0001-6820-5748

1 to 10 of 17Source PubMed

See all 17 authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Breast NeoplasmsMajor topic
Carcinoma, Transitional CellMajor topic
ImmunoconjugatesMajor topic
Animals
Cell Adhesion Molecules
Cell Line, Tumor
Female
Humans
Mice

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by47

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.

PMIDTitleJournalYearIn PapersSource
42,955,934Enhanced enfortumab vedotin sensitivity in a cisplatin-resistant bladder cancer model.PLoS One2026https://conductscience.org/library/papers/42955934PubMed
42,676,452Mechanisms of resistance to antibody-drug conjugates in bladder cancer.Front Pharmacol2026https://conductscience.org/library/papers/42676452PubMed
42,547,622The next generation of antibody-drug conjugates.Nat Med2026https://conductscience.org/library/papers/42547622PubMed
42,431,869Combined therapy with ALK inhibitors and a novel EGFR-targeting antibody‒drug conjugate as a strategy for ALK-rearranged non-small cell lung cancers.Oncogenesis2026https://conductscience.org/library/papers/42431869PubMed
41,943,470Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives.Cancer Biol Med2026https://conductscience.org/library/papers/41943470PubMed
41,789,080Clinical applications of antibody-drug conjugates in advanced non-small cell lung cancer.Front Immunol2026https://conductscience.org/library/papers/41789080PubMed
41,754,938Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics2026https://conductscience.org/library/papers/41754938PubMed
41,744,867Predictors of Response and Mechanisms of Resistance to Antibody Drug Conjugates in Urothelial Carcinoma.Curr Oncol2026https://conductscience.org/library/papers/41744867PubMed
41,668,804Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters.Cancer Drug Resist2026https://conductscience.org/library/papers/41668804PubMed
41,656,479Bispecific antibody-drug conjugates: a modular blueprint for next-generation cancer therapeutics.Arch Pharm Res2026https://conductscience.org/library/papers/41656479PubMed

1 to 10 of 47

See all 47 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35534238

GET https://conductscience.org/api/papers/v1/35534238/cited_by?page=2

API referenceFor AI assistants